Extended Prophylactic Antibiotics for Mastectomy with Immediate Breast Reconstruction: A Meta-analysis

Yang Hai, MD*  
Weelic Chong, BA†  
Melissa A. Lazar, MD‡

Background: The risk of surgical site infection (SSI) for breast surgery in patients without additional risk factors is low, below 5%. Evidence shows the risk of SSI is significantly elevated in patients undergoing immediate breast reconstruction (IBR). However, there is no consensus regarding the use of extended antibiotic prophylaxis. We aim to determine the effect of extended antibiotic prophylaxis on the incidence of SSI after IBR.

Methods: PubMed and Scopus were searched by 2 independent reviewers. Data abstracted included types of study, basic characteristics, detailed antibiotic prophylaxis information, SSI event, and other secondary outcomes. We calculated the risk ratio (RR) and 95% confidence interval (CI) for each study and used a random-effects model to estimate the results. Study quality, bias, and heterogeneity were also analyzed.

Results: A total of 11 studies (15,966 mastectomy procedures) were included. We found an overall 5.99% SSI rate in our population. Three studies comparing topical antibiotics with no topical antibiotics demonstrated statistical significance (RR = 0.26, 95% CI: 0.12–0.60, P = 0.001), whereas 8 studies comparing extended systemic antibiotics with standard of care found no statistical significance (RR = 0.80, 95% CI: 0.60–1.08, P = 0.13).

Conclusions: In the setting of IBR following mastectomy, there is insufficient evidence for the use of extended prophylactic antibiotics to reduce SSI rates. Well-designed randomized controlled trials in patients undergoing IBR should be conducted to determine the appropriate regimen and/or duration of prophylactic antibiotics on SSI outcomes. (Plast Reconstr Surg Glob Open 2020;8:e2613; doi: 10.1097/GOX.0000000000002613; Published online 27 January 2020.)

INTRODUCTION

Breast cancer is one of the most common malignancies diagnosed in women and comprises about 18% of all female cancers.¹ Surgery is the primary modality for the treatment of breast cancer, depending on tumor stage.² An increasing number of breast cancer patients are opting for mastectomy with reconstruction for treatment.

Postmastectomy reconstruction can surgically restore the shape of the breast and provide breast cancer patients with psychological benefits.³,⁴ There are 2 types of postmastectomy reconstructions: autologous flap and tissue expander/implant. Although autologous tissue provides the most lasting and natural outcomes, implant-based breast reconstruction is the more popular procedure, accounting for about 80% of postmastectomy reconstructions.⁵,⁶ Breast reconstruction can be divided by timing into immediate breast reconstruction (IBR) and delayed breast reconstruction (DBR). IBR, compared to DBR, offers a native inframammary fold and a pliable skin envelope for a more natural appearance.⁷ IBR also reduces psychological impact on patients⁸ and thus may be favored by some patients. However, compared to DBR, IBR is associated with greater risk of surgical site infection (SSI).⁹,¹⁰ SSI is defined as infection of the superficial incision, organ, and/or space after surgery. Accordingly, there are 3 categories of SSI: superficial incisional SSI, deep incisional SSI, and organ/space SSI.¹¹ The rate of SSI is strongly

Disclosure: The authors have no financial interest to declare in relation to the content of this article.

Related Digital Media are available in the full-text version of the article on www.PRSGlobalOpen.com.
associated with the type of surgical wound. The Centers for Disease Control (CDC) published a guideline in 1985,12 which classified surgical wounds into clean, clean/contaminated, contaminated, and dirty, with the SSI rate of 1%–5%, 3%–11%, 10%–17%, and over 27%, respectively.13 The occurrence of SSI can impact the postoperative recovery process and result in extra cost and rate of hospital readmissions.

Breast surgeries are classically categorized as clean,14 and according to the CDC and the Surgical Care Improvement Project, for breast surgical procedures, antibiotics should be discontinued within 24 hours after surgery.12 However, among breast surgeries, IBR with a tissue expander/implant is associated with higher SSI, with the average SSI rate ranging from 5% to as high as 35%,10,15,16

In the setting of IBR, several studies supported the use of extended prophylactic antibiotics to prevent SSI,17–19 but others stated that extended antibiotic usage could lead to systemic side effects and the development of resistant organisms.20–22 Thus, there is still no consensus regarding the extended usage, regimens, and timing of prophylactic antibiotics for mastectomy with IBR. This meta-analysis aims to determine the efficacy and safety of extended prophylactic antibiotics on SSI after mastectomy with IBR.

PATIENTS AND METHODS

Search Strategy

Our study followed guidelines published by the Centre for Reviews and Dissemination (CRD) and the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria.23,24 A protocol for this systematic review was registered using Prospero (CRD42019127536).

We included patients undergoing mastectomy with IBR, or mixed types (IBR and DBR) if the study had separate outcomes for IBR and DBR groups. Both randomized controlled trials (RCTs) and observational studies were included. Studies that compare pre-, peri-, postoperative extended prophylactic antibiotics with standard of care were included. Studies with no comparison group were excluded.

Two reviewers independently assessed the study quality using the Newcastle–Ottawa Scale.25 The Newcastle–Ottawa Scale is used to evaluate non-RCTs, with 1 version for case–control studies and the other for cohort studies. Both versions of the scale consist of 8 multiple-choice questions that address subject selection and comparability (of cases and controls in case–control studies and of cohorts in cohort studies) and the assessment of the outcome (in case–control studies) or exposure (in cohort studies).

Dealing with Missing Data

For those articles which met inclusion criteria but had incomplete data (ie, missing type of standard of care of comparison group, or no details of antibiotic use of extended antibiotics group), we emailed the corresponding author of that article. If corresponding authors did not respond after 3 weeks, the article was labeled as having incomplete data, and this would be mentioned in the results section.

Outcome Measures and Data Synthesis

All statistical analyses were performed by Review Manager V.5.3 (The Cochrane Collaboration, Software Update, Oxford, UK). We calculated the risk ratio (RR) at 95% confidence interval (CI) for each study, weighted by the number of events in each study. Statistical significance was defined as 2-tailed alpha < 0.05. Forest plots were generated for graphical presentations for clinical outcomes, and we used F statistics to define the heterogeneity of each study. Mantel-Haenszel method was used to conduct meta-analysis, and because F was >50%, we used the random-effects model instead of the fixed-effects model. We did subgroup analyses where the data were applicable.

Assessment of Heterogeneity

We assessed the heterogeneity between study results using the F statistics. The result is a percentage of total variation among studies due to heterogeneity. F is commonly divided into 3 categories—low, moderate, and high, with upper limits of 25%, 50%, and 75%, respectively.26

Sensitivity Analysis

We assessed the influence of a single study on the overall effect by sequentially removing 1 study at a time to test the robustness of the pooled results to further verify whether any study had an excessive influence on the overall results.

RESULTS

Results of the Search

A total of 597 articles were identified, of which 297 articles were excluded as they were ineligible publication types. After initial screening of the remaining 300 original articles, we further excluded 289 articles because they were irrelevant to our study topic or had incomplete data. The details of the search strategy are shown in Fig. 1.

Characteristics of Included Studies

A total of 11 studies (15,966 mastectomy procedures) were included, 10,688 in the extended antibiotics arm and
5,278 in the comparison arm. One was an RCT,\textsuperscript{21} and 10 studies\textsuperscript{17–20,22–27,31} were retrospective studies with 1 matched cohort study.\textsuperscript{31} The studies were published between 2009 and 2018, with sample sizes ranging from 112 to 7,443 mastectomies. The main characteristics of all 11 studies are presented in Table 1.

**Type of Procedures**

All procedures were unilateral or bilateral mastectomy with IBR. Immediate breast implant, tissue expander, and autologous flap (including latissimus dorsi flap and subpectoral flap) placement were described in 7, 3, and 2 studies, respectively.

**Timing and Types of Antibiotics**

Eight studies evaluated the usage of extended postoperative systemic prophylactic antibiotics compared to standard of care, where antibiotics are discontinued within 24 hours after breast surgery.\textsuperscript{12} However, the duration and types of antibiotics used vary between studies. In 5 of 8 studies,\textsuperscript{17,18,21,22,31} all patients were given pre- or perioperative antibiotics as baseline treatment, whereas the other 3 studies\textsuperscript{20,29,30} had incomplete data on antibiotic usage in their comparison groups. The study design was also different. Of the 8 studies, 1 study was an RCT, 2 studies were claims databases with a large sample size, and 5 studies were single-site retrospective studies.

Three studies evaluated the usage of postoperative topical antibiotics compared to no postoperative topical antibiotics. Two articles\textsuperscript{19,28} focused on the usage of topical mupirocin ointment and irrigation with both the extended antibiotics group and comparison arm using the same pre-/peri- and postoperative antibiotics. The third article\textsuperscript{27} used a novel antibiotic bead compared to comparison, where both arms had the same preoperative and irrigation antibiotics.

**Synthesis of Results**

**Incidence of SSI**

We found an overall average SSI rate of 5.99% in mastectomy procedures. Heterogeneity within the interventions used in the study prevented pooling of all the studies for analysis. Analysis of 8 studies comparing extended systemic antibiotics with standard of care found no statistical significance (RR = 0.80, 95% CI: 0.60–1.07, \(P = 0.13\)) (Fig. 2); as 1 RCT and
2 claims database studies are in the group of 8 studies, we also conducted other sensitivity analysis to check whether these studies may have affected the results (see further “Sensitivity Analysis” section). For the topical antibiotics group, analysis of the 3 studies comparing topical antibiotics with no topical antibiotics demonstrated statistically significant effect of antibiotics on reducing the incidence of SSI (RR = 0.26, 95% CI: 0.12–0.60, \(P=0.001\)) (Fig. 3) However, this statistical significance has to be interpreted with caution, as more research is needed to confirm the findings. The use of topical mupirocin ointment and the use of novel antibiotic beads may not be generalizable to many other centers’ experiences.

### Wound Complications

Wound complications included hematoma, wound dehiscence, seroma, hematoma, and mastectomy flap necrosis. Four studies measured the incidence of wound complications, with 9,789 mastectomies on extended prophylactic antibiotics and 4,220 mastectomies on standard of care. Analysis of the 4 studies comparing extended prophylactic antibiotics with standard of care found no statistically significant effect on reducing the incidence of wound complications (RR = 0.89, 95% CI: 0.78–1.03, \(P=0.12\)). The result is presented in Supplemental Digital Content 1, which displays a forest plot of wound complications subgroup analysis, [http://links.lww.com/PRSGO/B293](http://links.lww.com/PRSGO/B293).

### Hospital Readmission

Only 1 study measured the incidence of hospital readmission, with 6,049 mastectomies on extended prophylactic antibiotics and 1,349 mastectomies on standard of care. Analysis of the study comparing extended prophylactic antibiotics with standard of care found no statistical significance in reducing the rate of hospital readmission (RR = 1.22, 95% CI: 0.85–1.74, \(P=0.28\)). The result is presented in Supplemental Digital Content 2, which displays forest plot of readmission subgroup analysis, [http://links.lww.com/PRSGO/B294](http://links.lww.com/PRSGO/B294).

---

### Table 1. Characteristics of Included Studies (n = 11)

| Study | Study Design | Type of Reconstruction | No. Operations | Intervention Group Antibiotics | Intervention Group SSI (%) | Control Group Antibiotics | Control Group SSI (%) |
|-------|--------------|------------------------|----------------|-------------------------------|----------------------------|--------------------------|----------------------|
| Avashia et al | Retrospective IBR TE | 138 | Postoperative > 24 h | 8/119 (6.7%) | Standard of care | 6/19 (31.6%) |
| Hunsicker et al | Retrospective IBR implant | 535 | Postoperative irrigation for 96 h | 6/316 (1.9%) | Standard of care + irrigation once | 14/219 (6.4%) |
| Clayton et al | Retrospective IBR implant | 250 | Postoperative > 24 h | 21/116 (18.1%) | Standard of care | 46/134 (34.3%) |
| Goh et al | Retrospective IBR TE, latissimus dorsi, subpectoral | 240 | Postoperative > 24 h | 12/145 (8.3%) | Standard of care | 2/95 (2.1%) |
| Kenna et al | Retrospective IBR implant | 127 | Irrigation + antibiotic beads | 1/68 (1.47%) | Standard of care | 7/59 (11.8%) |
| McCullough et al | Retrospective IBR implant | 378 | Postoperative > 24 h | 24/200 (12%) | Standard of care | 24/178 |
| Murray et al | Retrospective IBR TE | 200 | Topical ointment | 0/23 (0%) | Standard of care | 10/177 |
| Olsen et al | Retrospective IBR implant, flap, both | 5,938 | Postoperative > 24 h | 240/3,305 (7.26%) | Standard of care | 213/2,633 |
| Phillips et al | RCT IBR implant | 112 | Postoperative > 24 h | 11/50 (22%) | Standard of care | 12/62 |
| Ranganathan et al | Retrospective IBR implant | 7,443 | Postoperative > 24 h | 166/6,049 (5.26%) | Standard of care | 41/1,394 |
| Townley et al | Retrospective IBR implant | 605 | Postoperative > 24 h | 9/297 (3.03%) | Standard of care | 11/308 (3.6%) |

TE, tissue expander.

---

![Fig. 2. Forest plot of studies that compared systemic antibiotics to standard of care (n = 8). SOC, standard of care. RR, risk ratio. M-H, Mantel-Haenszel.](http://links.lww.com/PRSGO/B293)
Quality Assessment for Included Studies

We created a quality assessment figure based on the Risk of Bias Tool found in the Cochrane Handbook for Systemic Reviews of Interventions, and we presented the percentages of risk in each of the 9 domains. High-quality responses were marked “low risk.” The result is shown in Supplemental Digital Content 3, which displays risk of bias, http://links.lww.com/PRSGO/B295.

Sensitivity Analysis and Publication Bias

Funnel plot analysis disclosed no asymmetry around the axis, which means that publication bias was not detected (Fig. 4). No significant results were identified in the “leave one out” sensitivity test.

Further Sensitivity Analysis to Understand Heterogeneity across Studies

As there were substantial differences in the types of studies within the 8 studies that investigated extended antibiotics on SSI, we conducted 2 further analyses. First, we noted that 2 studies using claims database had 88.5% of the weight (Fig. 2). We analyzed extended systemic antibiotics with and without the 2 claims database studies, resulting in 8 and 6 studies (Fig. 2) [see figure, Supplemental Digital Content 5, which displays a forest plot of extended systemic prophylactic antibiotics (without 2 claims databases), http://links.lww.com/PRSGO/B297]. In Fig. 2, RR was 0.80 (95% CI: 0.60–1.07, F = 61%). In Supplemental Digital Content 5, which displays a forest plot of extended systemic prophylactic antibiotics (without 2 claims databases) [http://links.lww.com/PRSGO/B297], RR was 0.93 (CI: 0.49–1.80, F = 79%). Both analyses showed no overall significance, but statistical heterogeneity increased slightly. We conclude that claims databases, even with their larger sample sizes, did not greatly alter the RR in this instance. We also note that a random-effects model is more accurate than a fixed-effects model due to the heterogeneity of the studies included.

There was 1 RCT among our included studies, and we were interested in its effect (or lack thereof) on the meta-analysis. Taken alone, the RCT reported no differences between 24-hour antibiotics or extended antibiotics (until drain removed), with an RR of 1.18 (95% CI: 0.47–2.95). We conducted an analysis of extended systemic antibiotics with and without this RCT, resulting in 8 and 7 studies [Fig. 2; also see figure, Supplemental Digital Content 4, which displays a forest plot of extended systemic prophylactic antibiotics (without RCT study), http://links.lww.com/PRSGO/B296]. In Fig. 2, RR was 0.80 (95% CI: 0.60–1.07, I² = 61%). The weight of the RCT was 0.7%. In Supplemental Digital Content 4, which displays a forest plot of extended systemic prophylactic antibiotics (with RCT study), RR was 0.77 (95% CI: 0.56–1.06, I² = 65%). Overall, the RCT did not change the results of the 8 studies. We note that given the nature of the study, theoretically the RCT should have been given more weight, but our predefined statistical method did not provide allowances for ad hoc increases in statistical weight.

DISCUSSION

For patients who are opting for mastectomy with reconstruction as treatment, IBR, especially implant-based IBR, has become a common procedure to restore the shape of the breast and improve psychological well-being. Breast surgery is historically thought of as a “clean” procedure, and for clean surgical procedures, the CDC calls for the discontinuation of perioperative prophylactic antibiotics within 24 hours. In recent years, some have advocated breast surgeries as “clean-contaminated” procedures, noting the breast microbiome and bacteria presence on normal breast implants, and of contamination of breast implants even when precautions are taken. However, this may be more complicated than applying a blanket label for all breast surgeries, because the SSI rates after different breast surgeries have varied widely in the published literature, ranging from 0.8% to 26%. Among all types of procedures, mastectomy with implant-based IBR has a 2-fold increase in SSI incidence compared with mastectomy.
into 3 categories—low, moderate, and high, with upper
tion of variability among different studies. Thus, meta-
of heterogeneity is only 1 component of a wider evalua-
tude SSI. Thus, having clarity of what makes an SSI would
a combination of the following could technically consti-
requirement for removal of the implant or expander, and
Redness, fever, requirement for intraoperative irrigation,
particular for our studies, antibiotics were not used uni-
observed level of inconsistency across different studies. In
analysts must also consider the clinical applications of the
Disagreement on what constitutes an SSI is a commonly
be very important for any prospectively designed study.
the incidence of SSI after IBR. The average SSI rate of
antibiotic protocols for the comparison groups and most
out of the 11 studies lacked adequate descriptions of their
which are mostly related to the studies that were analyzed.
First, there are missing data in some of the studies. Three
of the studies in a forest plot, but given the heterogeneity of the studies included, this was not statistically or clinically appropriate. Further subgroup analysis demonstrated that extended antibiotic prophylaxis showed no significant effect on reducing the incidence of wound complications and hospital readmission.
This is the first meta-analysis focusing on the effects of using extended prophylactic antibiotics for postmastectomy IBR in both topical and systemic antibiotics groups. However, there are several limitations in our meta-analysis, which are mostly related to the studies that were analyzed. First, there are missing data in some of the studies. Three out of the 11 studies lacked adequate descriptions of their antibiotic protocols for the comparison groups and most studies lacked antibiotic protocols and a defined time of discontinuation.
The second limitation was the heterogeneity of the included studies. As we mentioned earlier, we divided $F$ into 3 categories—low, moderate, and high, with upper limits of 25%, 50%, and 75%. The average $F$ of our studies is around 60%. According to a previous review, a quarter of meta-analyses has $F$ values over 50%, and quantification of heterogeneity is only 1 component of a wider evaluation of variability among different studies. Thus, meta-analysts must also consider the clinical applications of the observed level of inconsistency across different studies. In particular for our studies, antibiotics were not used uniformly in terms of regimens, timing, dosing, and duration. There was no indication that there was any standardization of what constituted an SSI in the included articles. Redness, fever, requirement for intraoperative irrigation, requirement for removal of the implant or expander, and a combination of the following could technically constitute SSI. Thus, having clarity of what makes an SSI would be very important for any prospectively designed study. Disagreement on what constitutes an SSI is a commonly encountered problem when comparing articles discussing infection rates, as it may be field specific. We would like to engage stakeholders and experts in the area of breast reconstruction to potentially form a consensus for prospective studies that will improve evidence-based practices.

The third limitation is the type of studies included. Ten of 11 studies were retrospective studies. Since there was only 1 RCT conducted within the included studies, more well-designed RCTs should be conducted to demonstrate the effect of different regimens of prophylactic antibiotics on the SSI rate of IBR. Appropriate prophylactic antibiotic protocols should be tested. Finally, a better reporting system of the types of SSI, antibiotic regime/ dosage/duration, and other complications should be used for future studies.

Future Directions
Given the paucity of prospective studies on this important topic, well-designed studies are sorely needed. However, there are many prior considerations that go into a well-designed prospective study for this particular question. Although we try not to prescribe particular rules here, the following questions (among others) are important to consider. Should patients with tissue necrosis be excluded? Should cases done by surgeons who leave completely different flap thicknesses be grouped together? Should reconstructions going under the muscle be compared to reconstructions done above the muscle? Should small areas of necrosis count the same as larger areas? Should the experience of the plastic surgeon be assessed? Should drain removal be based on drainage volume or based on duration, and if so, how much? Should patients who are discharged from hospital with a drain be grouped separately? It has been noted that these factors, while important in predicting SSI, are never available from retrospective chart reviews. Importantly, regarding antibiotic duration, the timepoints of antibiotics for 24 hours only, antibiotics until drain removal (which can vary significantly), and antibiotics for a certain duration after drain removal are essential to study and compare. Even if the sample size is relatively low, such well-controlled prospective studies will be valued. We rally surgeons in this field to consider starting prospective studies on this.

CONCLUSIONS
From our systematic review and meta-analysis, we conclude that, at this point, in part due to the lack of large prospective studies and in part due to the heterogeneity of interventions, there are insufficient data to suggest that extended antibiotics reduce the risk of SSI in patients undergoing mastectomy with IBR. Moreover, broad-spectrum antibiotics may significantly influence the normal gastrointestinal flora and lead to unfavorable clinical consequences, such as Clostridium difficile–related pseudomembranous colitis and antibiotic resistance. Therefore, we appeal for RCTs that test if there is improved efficacy and safety of extended prophylactic antibiotics on IBR. In particular, focus should be put on the choice of antibiotic regimens, the treatment duration, and a standardized clinical criterion for SSI evaluation.
ACKNOWLEDGMENT

We would like to acknowledge the critical feedback and intellectual contributions of the peer reviewers of this article.

REFERENCES

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321:624–628.
2. Matsen CB, Neumayer LA. Breast cancer: a review for the general surgeon. JAMA Surg 2013;148:971–979.
3. Schmauss D, Machens HG, Harder Y. Breast reconstruction after mastectomy. Front Surg 2015;2:71.
4. Senkus E, Kyrilakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:ix–30.
5. Hanna KR, Tilt A, Holland M, et al. Reducing infectious complications in implant based breast reconstruction: impact of early expansion and prolonged drain use. Ann Plast Surg 2016;76 Suppl 4:S312–5.
6. Platt J, Baxter N, Zhong T. Breast reconstruction after mastectomy for breast cancer. CMAJ 2011;183:2109–2116.
7. Serletti JM, Fosnot J, Nelson JA, et al. Breast reconstruction after breast cancer. Plast Reconstr Surg 2011;127:124e–135e.
8. Zhong T, Hu J, Bagher S, et al. A comparison of psychological response, body image, sexuality, and quality of life between immediate and delayed autologous tissue breast reconstruction: a prospective long-term outcome study. Plast Reconstr Surg 2016;138:757–760.
9. Olsen MA, Nickel KB, Fox IK, et al. Comparison of wound complications after immediate, delayed, and secondary breast reconstruction procedures. JAMA Surg 2017;152:e172338.
10. Alderman AK, Wilkins EG, Kim HM, et al. Complications in postmastectomy breast reconstruction: two-year results of the Michigan breast reconstruction outcome study. Plast Reconstr Surg 2002;109:23–19.
11. Berrios-Torres SI, Umscheid CA, Battrler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg 2015;152:784–791.
12. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practice advisory committee. Infect Control Hosp Epidemiol 1999;20:250–78; quiz 279.
13. Cruse PJE, Foord R. The epidemiology of wound infection: a 10-Year Prospective Study of 62,939 wounds. Surg Clin North Am 1980;60:27–40.
14. Platt R, Zucker JR, Zaleznik DF, et al. Perioperative antibiotic prophylaxis and wound infection following breast surgery. J Antimicrob Chemother 1993;31 Suppl B:43–48.
15. Cohen JR, Carroll C, Tenenbaum MM, et al. Breast implant-associated infections: the role of the national surgical quality improvement program and the local microbiome. Plast Reconstr Surg 2015;136:921–929.
16. Phillips BT, Bishawi M, Dagum AB, et al. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? Plast Reconstr Surg 2013;131:1–13.
17. Avashia VJ, Mohan R, Berhane C, et al. Postoperative antibiotic prophylaxis for implant-based breast reconstruction with acellular dermal matrix. Plast Reconstr Surg 2013;131:453–461.
18. Clayton JL, Bazakas A, Lee CN, et al. Once is not enough: withholding postoperative prophylactic antibiotics in prosthetic breast reconstruction is associated with an increased risk of infection. Plast Reconstr Surg 2012;130:495–502.
19. Hunsicker LM, Chavez-Abraham V, Berry C, et al. Efficacy of vancomycin-based continuous triple antibiotic irrigation in immediate, implant-based breast reconstruction. Plast Reconstr Surg Glob Open 2017;5:e1624.
20. Goh SC, Thorne AL, Williams G, et al. Breast reconstruction using permanent Becker expander implants: an 18 year experience. Breast 2012;21:764–768.
21. Phillips BT, Fourman MS, Bishawi M, et al. Are prophylactic postoperative antibiotics necessary for immediate breast reconstruction? Results of a prospective randomized clinical trial. J Am Coll Surg 2016;222:1116–1124.
22. McCullough MC, Chu CK, Duggal CS, et al. Antibiotic prophylaxis and resistance in surgical site infection after immediate tissue expander reconstruction of the breast. Ann Plast Surg 2016;77:501–505.
23. Tacconelli E. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Lancet Infect Dis 2010;10:226.
24. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med 2009;6:e1000097.
25. Wells G, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2004 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed February 20, 2019.
26. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
27. Kenna DM, Irojah BB, Mudge K, et al. Absorbable antibiotic beads prophylaxis in immediate breast reconstruction. Plast Reconstr Surg 2018;141:486c–492c.
28. Murray JD, Elwood ET, Jones GE, et al. Decreasing expander breast infection: a new drain care protocol. Can J Plast Surg 2009;17:17–21.
29. Olsen MA, Nickel KB, Fraser VJ, et al. Prevalence and predictors of postdischarge antibiotic use following mastectomy. Infect Control Hosp Epidemiol 2017;38:1048–1054.
30. Ranganathan K, Sears ED, Zhong L, et al. Antibiotic prophylaxis after immediate breast reconstruction: the reality of its efficacy. Plast Reconstr Surg 2018;141:865–877.
31. Townley WA, Baluch N, Bagher S, et al. A single pre-operative antibiotic dose is as effective as continued antibiotic prophylaxis in implant-based breast reconstruction: a matched cohort study. J Plast Reconstr Aesthet Surg 2015;68:673–678.
32. Armino-Olivo S, Stiles CR, Hagen NA, et al. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the effective public health practice project quality assessment tool: methodological research. J Eval Clin Pract 2012;18:12–18.
33. Jeevan R, Mennie JC, Mohanna PN, et al. National trends and regional variation in immediate breast reconstruction rates. Br J Surg 2016;103:1147–1156.
34. Kataria K, Bagdia A, Srivastava A. Are breast surgical operations clean or clean contaminated? Indian J Surg 2015;77(Suppl 3):1360–1302.
35. Bartisch S, Ascherman JA, Whittier S, et al. The breast: a clean-contaminated surgical site. Aesthet Surg J 2011;31:802–806.
36. Urbaniaik C, Gloor GB, Brackstone M, et al. The microbiota of breast tissue and its association with breast cancer. Microbiol Immunol 2016;62:520–526.
37. Hieken TJ, Chen J, Hoskin TL, et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep 2016;6:30751.
38. Walker JN, Pinkner CL, Pinkner JS, et al. The detection of bacteria and matrix proteins on clinically benign and pathologic implants. *Plast Reconstr Surg Glob Open*. 2019;7:e2037.

39. Galdiero M, Larocca F, Iovene MR, et al. Microbial evaluation in capsular contracture of breast implants. *Plast Reconstr Surg*. 2018;141:23–30.

40. Degnim AC, Throckmorton AD, Boostrom SY, et al. Surgical site infection after breast surgery: impact of 2010 CDC reporting guidelines. *Ann Surg Oncol*. 2012;19:4099–4103.

41. Nahabedian MY, Tsangaris T, Momen B, et al. Infectious complications following breast reconstruction with expanders and implants. *Plast Reconstr Surg*. 2003;112:467–476.

42. Olsen MA, Nickel KB, Fox IK, et al. Incidence of surgical site infection following mastectomy with and without immediate reconstruction using private insurer claims data. *Infect Control Hosp Epidemiol*. 2015;36:907–914.

43. Lyle WG, Outlaw K, Krizek TJ, et al. Prophylactic antibiotics in plastic surgery: trends of use over 25 years of an evolving specialty. *Aesthet Surg J*. 2003;23:177–183.

44. Hunter JG. Commentary on: effectiveness of prophylactic antibiotics in outpatient plastic surgery. *Aesthet Surg J*. 2014;34:1259–1260.

45. Grunebaum LD, Reiter D. Perioperative antibiotic usage by facial plastic surgeons: national survey results and comparison with evidence-based guidelines. *Arch Facial Plast Surg*. 2006;8:88–91.

46. Parikh RP, Sharma K, Qureshi AA, et al. Quality of surgical outcomes reporting in plastic surgery: a 15-year analysis of complication data. *Plast Reconstr Surg*. 2018;141:1332–1340.